ライフサイエンスコーパス: placebo-controlled study

1 in sensitivity analyses (eg, when excluding placebo-controlled studies).

2 was a multicenter, randomized, double-blind, placebo-controlled study.

3 ients from healthy donors in a double-blind, placebo-controlled study.

4 were investigated in a pilot, double-blind, placebo-controlled study.

5 se of patients treated with ivacaftor in the placebo-controlled study.

6 that of patients who received placebo in the placebo-controlled study.

7 nts who had received active treatment in the placebo-controlled study.

8 Randomized, double-blind, placebo-controlled study.

9 o Bolivian Leishmania (v.) braziliensis in a placebo-controlled study.

10 This was a randomized placebo-controlled study.

11 eers underwent a randomized, double-blinded, placebo-controlled study.

12 d in a phase I, double-blind, multiple-dose, placebo-controlled study.

13 lled in a 6-month, randomised, double-blind, placebo-controlled study.

14 igation was a within-subjects, double-blind, placebo-controlled study.

15 , an event-driven, randomized, double-blind, placebo-controlled study.

16 in a randomized, three-armed, double-blind, placebo-controlled study.

17 rom CSU patients enrolled in a double-blind, placebo-controlled study.

18 III, randomized, double-masked, multicenter, placebo-controlled study.

19 horea, was well tolerated in a double-blind, placebo-controlled study.

20 II in case studies, cohort studies, and one placebo-controlled study.

21 owel syndrome in a randomised, double-blind, placebo-controlled study.

22 , prospective, 1:1 randomized, double-blind, placebo-controlled study.

23 EBV shedding in a randomized, double-blind, placebo-controlled study.

24 This was a randomized, double-blind, placebo-controlled study.

25 eart failure attended a series of randomized placebo-controlled studies.

26 se in two parallel, identical, double-blind, placebo-controlled studies.

27 ed recent-onset AF and was well tolerated in placebo-controlled studies.

28 ted in a series of randomized, double-blind, placebo-controlled studies.

29 ent will be determined by ongoing randomized placebo-controlled studies.

30 > or = 65 years, using data pooled from two placebo-controlled studies.

31 systematic evaluation in large, randomized, placebo-controlled studies.

32 an AE profile consistent with those seen in placebo-controlled studies.

33 In this double-blind, randomized, crossover, placebo-controlled study, 15 subjects with DSM-IV bipola

34 AND PARTICIPANTS: In a phase 2 double-blind, placebo-controlled study, 159 patients (median [SD] age,

35 In this randomized, double-blind, placebo-controlled study, 16 malaria-naive, glucose-6-ph

36 In this double-blind, randomized, crossover, placebo-controlled study, 22 subjects with DSM-IV treatm

37 -month dose-response randomized double-blind placebo-controlled study, 221 polysensitized subjects wi

38 e II, multicentre, randomised, double-blind, placebo-controlled study, 249 patients with RRMS, aged 1

39 In this double-blind, placebo-controlled study, 290 subjects were randomized t

40 In a double-blind placebo-controlled study, 36 female patients with IBS-C

41 In this double-blind, placebo-controlled study, 40 healthy male subjects were

42 In this double-blind, randomized, placebo-controlled study, 55 children, 5 to 11 years of

43 In a randomized double-blind placebo-controlled study, 56 patients with moderate-seve

44 In this double-blind, placebo-controlled study, 57 patients with RP secondary

45 In a randomized, double-blind, placebo-controlled study, 60 patients with fibrotic IIP

46 In a 12-week, double-blind, placebo-controlled study, 60 treatment-resistant childre

47 In this double-blind, randomized, placebo-controlled study 68 subjects aged 12 to 45 years

48 this multicenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut al

49 s.In this 12-wk, double-blinded, randomized, placebo-controlled study, 76 vegans received either a pl

50 In this phase III, parallel, double-blind, placebo-controlled study, 766 patients with moderate-to-

51 In this prospective randomized placebo-controlled study, a single subcutaneous dose of

52 In a double-blind placebo-controlled study, adult participants (18-65 year

53 this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite N

54 In this phase III, randomised, double-blind, placebo-controlled study, adults from 63 sites in 23 cou

55 In a randomized, blinded, placebo-controlled study, adults were challenged with mo

56 This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical

57 ransmembrane conductance regulator (CFTR) in placebo-controlled studies and patients aged 6-11 years

58 d onto a phase III, multicenter, randomized, placebo-controlled study and administered placebo or DA

59 luded 2 studies: a randomized, double-blind, placebo-controlled study and an open-label extension stu

60 re of 4-6 were randomized in a double-blind, placebo-controlled study, and 488 of these patients rece

61 dose (25-1200 mg), double-blind, randomised, placebo-controlled study, and part 2, an open-label, ran

62 Results from large scale placebo-controlled studies are awaited.

63 athic pulmonary fibrosis, although data from placebo-controlled studies are lacking.

64 More placebo-controlled studies are needed in this area to de

65 Placebo-controlled studies are needed to confirm whether

66 Larger placebo-controlled studies are needed to fully assess ef

67 -related food allergy is not clear, and more placebo-controlled studies are needed.

68 quate follow-up and in particular randomized placebo-controlled studies are required to confirm these

69 This phase 1 placebo-controlled study assessed safety and immunogenic

70 This placebo-controlled study assessed the effects of the onc

71 ofile of REG1 in a randomized, double-blind, placebo-controlled study, assigning 50 subjects with cor

72 nter, prospective, randomized, double-blind, placebo-controlled study at 2 tertiary medical centers o

73 6-05 was a 36-week randomised, double-blind, placebo-controlled study at 25 centres in the USA.

74 We did this double-blind, placebo-controlled study at 35 hospitals in Canada, Fran

75 icentre, parallel, randomised, double-blind, placebo-controlled study at 37 sites (hospitals and spec

76 We did this randomised, double-blind, placebo-controlled study at 38 hospitals in 19 countries

77 is randomised, double-blind, parallel-group, placebo-controlled study at 49 hospitals in seven Europe

78 We did a phase 2, randomised, double-blind, placebo-controlled study at 51 centres in the USA, Canad

79 A randomized, placebo-controlled study based on preclinical and clinic

80 In this first placebo-controlled study, canakinumab was effective in p

81 Conclusion: In this 12-week, randomized, placebo-controlled study, cilofexor was well tolerated a

82 ulin regulation of lipolysis.A double-blind, placebo-controlled study compared 6 mo of 3.9 g eicosape

83 participating in a randomized, double-blind, placebo-controlled study comparing 28 weeks of IPT antep

84 disease onset in a total of four randomized, placebo-controlled studies conducted in rabbits and monk

85 Double-blind, placebo-controlled study conducted among 380 patients wh

86 rbamazepine, was assessed in a double-blind, placebo-controlled study conducted from September 2014 t

87 Double-blind, randomized placebo-controlled study conducted in 29 centers in the

88 ere assessed in a multicentre, double-blind, placebo-controlled study conducted in 483 patients with

89 were included in a randomized, double-blind, placebo-controlled study conducted in Switzerland betwee

90 A 24-month, double-blind, placebo-controlled study, conducted at 9 sites in the Un

91 This randomized, double-blind, placebo-controlled study consisted of 2 parts.

92 This randomized, double-blind, placebo-controlled study consisted of 2 test days during

93 In a double-blind placebo-controlled study, critically ill intubated patie

94 In X-ACT, a phase III, double-blind, placebo-controlled study, CSU patients (18-75 years) wit

95 A previous randomized, placebo-controlled study demonstrated that grass allerge

96 ge chamber using a monocenter, double-blind, placebo-controlled study design.

97 cularis monkeys were used in a double-blind, placebo-controlled study design.

98 fibrate (FFB) (160 mg/day) in a single-blind placebo-controlled study design.

99 ye Disease Study 2 (AREDS2) is a randomized, placebo-controlled study designed to determine whether s

100 RN-HIV) trial is a randomized, double-blind, placebo-controlled study, designed to investigate the ef

101 T was a three-part, randomised, multicentre, placebo-controlled study done at 22 centres in the USA,

102 IT2 was a two part, randomised, multicentre, placebo-controlled study done at 38 centres in 12 countr

103 RISE-IIP was a double-blind, randomised, placebo-controlled study done at 65 pulmonary hypertensi

104 this multicentre, double-blind, randomised, placebo-controlled study done in 48 acute care hospitals

105 In this phase 3, randomised, observer-blind, placebo-controlled study, done at 77 centres worldwide,

106 In a randomized, placebo-controlled study, either protein C or placebo wa

107 In this phase 3, randomised, double-blind, placebo-controlled study, eligible patients aged 2-65 ye

108 Methods: This prospective, double-blind, placebo-controlled study enrolled 10 patients with bioch

109 III, double-blind, randomized, multicenter, placebo-controlled study, established the efficacy and s

110 (ACT)-1 and ACT-2 randomized, double-blind, placebo-controlled studies evaluated infliximab inductio

111 A multicenter, randomized, double-blind, placebo-controlled study evaluated 3 regimens of grass a

112 A randomized, double-blind, placebo-controlled study evaluated an adjuvanted bivalen

113 This randomized, double-blind, placebo-controlled study evaluated safety, tolerability,

114 This randomized, double-blind, placebo-controlled study evaluated the effects of oral l

115 This phase II randomized, double-blinded, placebo-controlled study evaluated the efficacy of vorin

116 This phase 1/2, randomized, placebo-controlled study evaluated the immunogenicity an

117 multicenter, randomized (1:1), double-blind, placebo-controlled study evaluated the safety and effica

118 uninfected adults were enrolled in 6 blinded placebo-controlled studies evaluating the immunogenicity

119 was a multicenter, randomized, double-blind, placebo-controlled study evaluating quinapril 80 mg/day,

120 TECOS was a randomized, double-blind, placebo-controlled study evaluating the CV safety of sit

121 To conduct a robust, double-blind, placebo-controlled study examining the effects of tumor

122 GVHD treatment; however, recent randomized, placebo-controlled studies failed to corroborate these r

123 s, and carried out a double-blind randomized placebo-controlled study for 16 weeks, followed by an op

124 The MS-SPI randomised, double-blind, placebo-controlled study found that MD1003 improved disa

125 2000, a series of 10 individual double-blind placebo-controlled studies has evaluated newer antidepre

126 To date, no double-blind, placebo-controlled studies have been carried out that sp

127 A number of placebo-controlled studies have been completed or are un

128 Although a profusion of explanatory placebo-controlled studies have contributed little to de

129 Numerous placebo-controlled studies have demonstrated the ability

130 Placebo-controlled studies have not been conducted to ev

131 Several randomised placebo-controlled studies have shown that UDCA improves

132 In a phase 1, double-blinded, randomized, placebo-controlled study, healthy subjects were inoculat

133 Three independent placebo-controlled studies in healthy men were conducted

134 We performed a blinded, randomized and placebo-controlled study in 11 conscious patients (nine

135 ve days in a single-blind (patients masked), placebo-controlled study in 12 men with clinically stabl

136 is a multicentre, randomised, double-blind, placebo-controlled study in 3323 women with stage 1-3 br

137 Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of b

138 This was a randomized, double-blind, placebo-controlled study in 47 healthy volunteers of dos

139 We conducted a randomized, double-blind, placebo-controlled study in 77 subjects with diabetic ne

140 was a phase 1/2, randomized, observer-blind, placebo-controlled study in adults with multiple myeloma

141 did a multicentre, double-blind, randomised, placebo-controlled study in four hospitals in Kenya (two

142 In a double-blind, placebo-controlled study in healthy adults experimentall

143 In a subsequent double-blind, placebo-controlled study in healthy volunteers, we aimed

144 , an event-driven, randomized, double-blind, placebo-controlled study in patients hospitalized for he

145 , and had a good safety profile in a phase 3 placebo-controlled study in patients with advanced non-s

146 in a multicenter, randomized, double-blind, placebo-controlled study in patients with biopsy-confirm

147 This was a randomized, placebo-controlled study in patients with International

148 ticentre, phase 3, randomised, double-blind, placebo-controlled study in patients with tuberous scler

149 We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Behc

150 This was a randomized, double-blind, placebo-controlled study in which 68 individuals were ra

151 a randomized, double-blind, counterbalanced, placebo-controlled study in which we administered the br

152 This prospective, randomized, double blind, placebo-controlled study included 30 patients randomised

153 A double-blind, randomized, placebo-controlled study included 63 healthy female volu

154 e 2, multi-center, randomized, double-blind, placebo-controlled study included a 12-week treatment ph

155 e II, multicenter, randomized, double-blind, placebo-controlled study included the following: a 12-we

156 In three double-blind, placebo-controlled studies, intradermal avotermin (conce

157 e-center, phase 2, randomized, double-blind, placebo-controlled study investigated the safety, tolera

158 a first-in-human, randomized, double-blind, placebo-controlled study investigating the safety, toler

159 The prospective, placebo-controlled study involved exclusively breastfed

160 atients; a phase 3 randomized, double blind, placebo controlled study involving 186 patients; an open

161 a from a series of randomized, double-blind, placebo-controlled studies involving subjects with unipo

162 TIENTS: A phase 1 and 2 randomized, blinded, placebo-controlled study involving 65 patients with isch

163 this multicenter, randomized, double-blind, placebo-controlled study involving 66 patients, we evalu

164 RA), in a phase 2, randomized, double-blind, placebo-controlled study involving patients with psoriat

165 gnetic resonance imaging (MRI) in a phase 2, placebo-controlled study involving patients with relapsi

166 We conducted a phase 3, double-blind, placebo-controlled study involving untreated and previou

167 Randomized, double-blind, placebo-controlled study (Measuring Effects on Intima-Me

168 In this phase 3, double-blind, randomised, placebo-controlled study, men with non-metastatic castra

169 collected from two randomized double-blind, placebo-controlled studies: MENSA (NCT01691521: 32-week

170 Within a randomized double-blind placebo-controlled study (n = 115), we examined whether

171 This randomized, placebo-controlled study (NCT00985725) enrolled 143 adul

172 Despite robust data from randomized placebo-controlled studies, no treatments are licensed s

173 (Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effe

174 Few placebo-controlled studies of antibiotics have been done

175 25, 2015, from two randomised, double-blind, placebo-controlled studies of at least 32 weeks duration

176 Results were integrated from 2 double-blind, placebo-controlled studies of ecallantide treatment for

177 e field is strongly supported by blinded and placebo-controlled studies of IL-5 and oral viscous bude

178 bility data from 2 double-blind, randomized, placebo-controlled studies of infliximab plus methotrexa

179 was pooled from three phase III randomized, placebo-controlled studies of pirfenidone for IPF (the t

180 We conducted a double-blind, placebo-controlled study of 119 adults with moderate to

181 med a randomized Phase I/II, observer-blind, placebo-controlled study of 12 healthy, H pylori-negativ

182 -day, multicenter, randomized, double-blind, placebo-controlled study of 155 patients with nonconstip

183 A multicenter, randomized, double-blind, placebo-controlled study of 161 children and adolescents

184 This was a randomized, double-blind, placebo-controlled study of 22 439 subjects aged 50-59 y

185 , and Participants: Multicenter double-blind placebo-controlled study of 260 nonneutropenic, nontrans

186 rformed a 10-week, randomized, double-blind, placebo-controlled study of 281 patients with mildly to

187 a phase 1, randomized, partial double-blind, placebo-controlled study of 36 malaria-naive adults, all

188 a Phase I, randomized, partial double-blind, placebo-controlled study of 36 malaria-naive adults, all

189 med a randomized, double-blind, multicenter, placebo-controlled study of 420 patients with IBS-C give

190 We performed a randomized, double-blind, placebo-controlled study of 44 adults with IBS and diarr

191 onal and nonlesional skin in a double-blind, placebo-controlled study of 54 patients with moderate to

192 We conducted a randomized, double-blind, placebo-controlled study of 66 optimally-treated T2DM pa

193 We did a double-blind, placebo-controlled study of a device-based non-specific

194 Multicenter, randomized, double-masked, placebo-controlled study of acetazolamide in 165 partici

195 A randomized, double-blind, placebo-controlled study of allergic and nonallergic pat

196 confirmed this prediction empirically with a placebo-controlled study of cholinesterase inhibition.

197 participants of a randomized, double-blind, placebo-controlled study of daclizumab (DZB) and mycophe

198 viously reported the results of a randomized placebo-controlled study of egg oral immunotherapy (eOIT

199 reported the results of a 1-y double-blind, placebo-controlled study of embryonic dopamine cell impl

200 costeroid-sparing effects in a double-blind, placebo-controlled study of FIP1L1/PDGFRA-negative, cort

201 We conducted a double-blind, placebo-controlled study of GS-5806, an oral RSV-entry i

202 We conducted a randomized, double-blind, placebo-controlled study of IPTp comparing the standard

203 We conducted a randomized, double-blind, placebo-controlled study of lebrikizumab, a monoclonal a

204 is the standard treatment, yet no randomized placebo-controlled study of medical IOP reduction has be

205 harmacotherapy, a large, recently completed, placebo-controlled study of methylphenidate for preschoo

206 his was a 12-week, double-blind, randomized, placebo-controlled study of NAC in children with autisti

207 We conducted a double-blind, randomized, placebo-controlled study of nasal responses to live atte

208 rst year of life.A double-blind, randomized, placebo-controlled study of newborn infants assigned to

209 The authors conducted a randomized, placebo-controlled study of nicotine replacement therapy

210 ded this work in a randomized, double-blind, placebo-controlled study of patients with bipolar depres

211 We undertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular

212 In a placebo-controlled study of patients with IBS, a low FOD

213 ELBW; <1000 g) participating in a randomized placebo-controlled study of probiotic supplementation.

214 Report a double-blind, placebo-controlled study of rituximab in patients with a

215 atients who completed a 30-month randomized, placebo-controlled study of the effect of doxycycline on

216 nvestigated this hypothesis in a prospective placebo-controlled study of treated patients with hypert

217 We performed a randomized, double-blind, placebo-controlled study of two neutralizing, fully huma

218 e, randomized, double-blinded, double-dummy, placebo-controlled study of vitamin D(3) supplementation

219 Recent randomized placebo-controlled studies on chronic laryngitis, cough,

220 We conducted a 3-month, double-blind, placebo-controlled study on the effects of donepezil in

221 zed, single-centre, double-blind, crossover, placebo-controlled study, partial responders taking opti

222 In this phase 2A double-blind, randomised, placebo-controlled study, patients aged 18 years or olde

223 ot investigation followed by a double-blind, placebo-controlled study, patients with allergic rhiniti

224 In addition, vehicle- or placebo-controlled studies predominate over head-to-head

225 This was a multicenter, double-blind, placebo-controlled study randomizing subjects to 12 week

226 We did a multicentre, double-blind, placebo-controlled study (RESILIENT) at 38 academic clin

227 Initial data from a placebo-controlled study suggest faster time to recovery

228 To date, there have been no randomized, placebo-controlled studies supporting the efficacy of an

229 Randomized, double-blind, placebo-controlled studies that evaluated beta-blockers

230 and ARIES-2 trials were the pivotal 12-week, placebo-controlled studies that led to the regulatory ap

231 RD-5: two phase 3, randomized, double-blind, placebo-controlled studies that utilized the same sequen

232 ucted two phase 3, randomized, double-blind, placebo-controlled studies that were designed to assess

233 This was the first placebo-controlled study that also controlled for the co

234 We analyzed data from a phase 2, placebo-controlled study that evaluated the efficacy and

235 Here, we report a double-blind, placebo-controlled, study that examined specific effects

236 In this randomized, double-blind, placebo-controlled study the safety, tolerability, and c

237 In this placebo-controlled study, the authors tested the cogniti

238 In a randomized, placebo-controlled study, the safety and immunogenicity

239 This randomized, double-blind, placebo-controlled study (TL7116958) was conducted over

240 y QOL-B-RSS, suggesting a continued need for placebo-controlled studies to establish the clinical ben

241 patients were randomized in a double-blind, placebo-controlled study to assess pseudobulbar affect w

242 nducted a 6-month, randomized, double-blind, placebo-controlled study to assess safety, tolerability,

243 This is the first placebo-controlled study to assess the effects of chroni

244 We conducted a randomized, double-blind, placebo-controlled study to assess whether raltegravir i

245 This is the first randomized, placebo-controlled study to demonstrate that antimycobac

246 We performed a randomized, placebo-controlled study to determine its effects on sym

247 We performed a placebo-controlled study to determine whether a delayed-

248 We conducted a double-blind, randomized, placebo-controlled study to evaluate the effect of gallo

249 A I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and sa

250 A randomized, double-blind, placebo-controlled study to evaluate the impact of oral

251 Here, we report the first double-blind placebo-controlled study to examine the effects of MDMA

252 We conducted a randomized, double-blind, placebo-controlled study to examine whether pioglitazone

253 performed a post hoc analysis of a phase III placebo-controlled study to identify characteristics of

254 ed a parallel, double-blind, randomized, and placebo-controlled study to investigate the effect of ph

255 en season were randomized in a double-blind, placebo-controlled study to receive 300IR 5-grass pollen

256 rhinitis were randomized in a double-blind, placebo-controlled study to receive 500 index of reactiv

257 were enrolled in a randomized, double-blind, placebo-controlled study to receive IV methylprednisolon

258 In this phase 3, double-blind, placebo-controlled study undertaken at 76 centres in Asi

259 were enrolled into a randomized double-blind placebo-controlled study using 4 weeks of slow-release m

260 We performed a randomized, placebo-controlled study using C1-INH in highly sensitiz

261 A randomized, double-blind, placebo-controlled study was conducted among 44 subjects

262 IIb, randomized, parallel-arm, double-blind, placebo-controlled study was conducted at 49 centers in

263 A double-blind, randomized, crossover, placebo-controlled study was conducted in 10 HET and 15

264 A prospective, multicenter randomized placebo-controlled study was conducted in 120 subjects f

265 se 2, multicenter, randomized, double-blind, placebo-controlled study was conducted in 138 patients w

266 A single-blind, randomized, placebo-controlled study was conducted in patients infec

267 A randomized, double-blind, placebo-controlled study was conducted in patients with

268 ternational, randomized (2:1), double-blind, placebo-controlled study was conducted to compare comple

269 h factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andex

270 This randomized, double-blind, placebo-controlled study was designed to compare humoral

271 This phase 3, double-blind, placebo-controlled study was done at 118 sites in 13 cou

272 This three-stage randomised, double-blind, placebo-controlled study was done at 59 clinical sites i

273 This randomised, double-blind, placebo-controlled study was done by movement disorder s

274 This phase 1, randomised, placebo-controlled study was done in two parts.

275 this prospective, randomized, double-blind, placebo-controlled study was to compare the effect of de

276 f this multicenter, prospective, randomized, placebo-controlled study was to evaluate and compare the

277 The aim of this randomized, double-blind, placebo-controlled study was to test the hypothesis that

278 This randomized, double-blind, placebo-controlled study was undertaken to examine the s

279 In a double-blind, placebo-controlled study we examined approach-avoidance

280 In this exploratory, double-blind, placebo-controlled study we recruited male patients (>/=

281 this multicenter, randomized, double-blind, placebo-controlled study, we assessed larazotide acetate

282 In our 6 week, randomised, double-blind, placebo-controlled study, we enrolled adults (aged >/=40

283 ase 2 multicentre, randomised, double-blind, placebo-controlled study, we enrolled participants aged

284 In this prospective, blinded, placebo-controlled study, we evaluated the hypothesis th

285 In this double-blind, placebo-controlled study, we investigated whether a sing

286 se 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patie

287 In this double-blind, placebo-controlled study, we randomly assigned 31 patien

288 In this randomized, double-blind, placebo-controlled study, we randomly assigned 32 HSCT r

289 In this double-blind, placebo-controlled study, we randomly assigned 5362 pati

290 In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patie

291 In this phase 3, multicentre, randomised, placebo-controlled study, we randomly assigned adults wi

292 In this international, double-blind, placebo-controlled study, we randomly assigned patients

293 In this double-blind, placebo-controlled study, we randomly assigned subjects

294 In this phase 2 randomised, double-blind placebo-controlled study, we recruited healthy adults (>

295 icentre, parallel, randomised, double-blind, placebo-controlled study, we recruited patients aged 18-

296 In a phase II double-blind, placebo-controlled study, we tested the safety and effic

297 In a placebo-controlled study, we used arterial spin labeling

298 We conducted a multicenter, randomized, placebo-controlled study with a 2-week single-blind run-

299 were enrolled in a double-blind, randomized, placebo-controlled study with pexacerfont (300 mg/day fo

300 sessed this hypothesis via a double-blinded, placebo-controlled study with the dopamine receptor agon